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Abstract: Hypersialylation of tumour cell surface proteins along with a marked up-regulation
of sialyltransferase (ST) activity is a well-established hallmark of cancer. Due to the critical
role of STs in tumour growth and progression, ST inhibition has emerged as a potential new
antimetastatic strategy for a range of cancers including pancreatic and ovarian. Human STs
are divided into subtypes based on their linkage and acceptor molecule, with each subtype
controlling the synthesis of specific sialylated structures with unique biological roles. This has
important implications for inhibitor development, as STs also play significant roles in immune
responses, inflammation, viral infection and neurological disorders. Thus, the current goal in
order to advance to the clinic is the development of subtype selective, cell-permeable and
synthetically accessible, small-molecule ST inhibitors. Herein, is a comprehensive review of
the latest developments in ST inhibitors from design, Nature and high-throughput screening,
addressing both the challenges and opportunities in targeting cell surface sialylation. The
review features an overview of the biological evaluation methods, computational and imaging
tools, inhibitor molecular diversity and selectivity towards ST subtypes, along with the
emerging role of ST inhibitors as diagnostic tools for disease imaging.
Key words: sialyltransferase inhibitors, structure-based design, anticancer agents,
antimetastasis, diagnostic tools.
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1. INTRODUCTION
Sialic acid is the body's most important sugar next to glucose.1 Sialylation, the addition of
sialic acid to cell surface molecules via sialyltransferase enzymes, is integral to cell function,
governing numerous important biological processes including cell-cell recognition, adhesion,
protein targeting and fertilization.2 However, aberrant sialylation is a hallmark of cancer, with
hypersialylation of up to 30% seen in many cancers, along with marked up-regulation of
sialyltransferase activity. This is directly correlated with increased metastatic potential and
poor patient prognosis.3,4 Sialylation mediates tumour metastasis via several routes including
stimulating tumour invasion and migration through integrin-mediated processes,5,6 promoting
tumour survival by blocking galectin binding,7 and inhibiting Fas-mediated apoptosis.4,8 Due
to the critical role of sialyltransferases (STs) in tumour metastasis, ST inhibition has emerged
as a potential new anti-metastatic treatment for several cancers.9
There are 20 human STs divided into four groups based on their linkage type and acceptor
molecule: ST3Gal I-VI; ST6Gal I-II; ST6GalNAc I-VI; and ST8Sia I-VI.10 Each ST controls
the synthesis of specific sialylated structures with unique biological roles, such as Lewis
antigen sialylation by ST3Gal III, IV and VI and β1 integrin sialylation by ST6Gal I.11 Thus,
it is critical for the advancement of this field that selective inhibitors are used to unravel the
roles of individual STs in tumour growth, metastasis and disease progression and for the
development of a new treatment strategy for a range of treatment resistant cancers including
pancreatic and ovarian cancer. Furthermore, resistance to frontline therapies such as paclitaxel
and the platinum-based drugs cisplatin and carboplatin, is a critical issue in cancer treatment
resulting in significant disease relapse, and reducing patient survival rates. Upregulation of
STs has been shown to produce cellular resistance in both paclitaxel and cisplatin treatment in
human ovarian and colorectal cancer cell lines along with reducing treatment efficacy.12 This
demonstrates that small molecule inhibitors of STs could be used either alone as a new
therapeutic treatment for selected cancers, or in combination with existing drugs to enhance
their sensitivity in resistant tumours.
Herein, we review the latest achievements in the development of ST inhibitors by design,
from Nature and from high-throughput screening (HTS), along with examining the emerging
role of ST inhibitors as biological tools for cancer imaging.
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A. Sialic Acid
Sialic acids belong to a family of sugars containing a nine-carbon backbone bearing a carboxy
group at the 1-position, a hydroxy group at the 2-position and an amino group at the 5position, with over 50 derivatives known.1,13 N-Acetylneuraminic acid, Neu5Ac (1) is the
most ubiquitous and well known member of this family alongside other important members
including the 5-glycolylamido derivative Neu5Gc (2) and the non-aminated derivative 2-keto3-deoxynononic acid, KDN (3) (Fig. 1).2,14 Higher animals and some microorganisms
biosynthesize sialic acids from ManNAc for use in many reactions. Ubiquitous components of
mammalian glycoproteins and glycolipids, they are a family of closely related neuraminic
acids found at the non-reducing terminal positions of glycoconjugates, usually attached to the
exposed terminus of N- and O-linked glycans of glycoproteins. Sialic acid thus represents one
of the most important constituents of glycoconjugates in biological systems.1,2,14

Figure 1. Structures of selected sialic acids.

Due to their terminal position and their negative charge at physiological pH, sialylated
oligosaccharide sequences are key information containing molecules and critical determinants
in cell-cell recognition processes, cell-matrix interactions and maintenance of serum
glycoproteins in the circulation.15,16 The cell surface sialic acid residues have been known to
act as receptors for the influenza virus.17 They are often function in the “anti-recognition” or
masking of the carbohydrate groups they terminate.16 The highest concentration of sialic acid
(as Neu5Ac) in the human body occurs in the brain where it is an integral part of ganglioside
structure. Consistent with this finding, human milk contains a high concentration of sialic
acid, which is associated with the increase of gangliosides in the brain and is potentially
linked to improved learning ability.18 Wang and Brand-Miller have reviewed the role of sialic
acid in human nutrition and the link between sialic acids, breastfeeding and learning
behaviour.19 Conversely, a reduction in sialic acid is correlated with erythrocyte destruction.20
B. Sialyltransferases
Sialyltransferases are a subset of glycosyltransferases (GTs) involved in the biosynthesis of
sialylated glycolipids and/or glycoproteins. Sialyltransferases catalyse the addition of sialic
acid residues from the β-glycoside donor cytidine monophosphate N-acetylneuraminic acid,
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CMP-Neu5Ac (4) (Fig. 2) to the terminal position of growing oligosaccharide chains of
glycoconjugate acceptors, to produce α-sialosides. In vertebrates, CMP-Neu5Ac is produced
in the cell nuclei and transported to the Golgi apparatus where sialylation takes place.21-23
Depending on the glycosidic linkage formed and their glycoconjugate acceptor, vertebrate
STs are arranged into four families (ST3Gal, ST6Gal, ST6GalNAc and ST8Sia; Table I). STs
families are further subdivided into 20 sub-types in mammals that are highly conserved from
mouse to man24 and more than 25 sub-types in lower vertebrates, each of them being
characterized by conserved amino acid positions. All utilise CMP-Neu5Ac as the activated
sugar donor to catalyse the transfer of sialic acid residues to terminal non-reducing positions
of oligosaccharide chains of glycoproteins and glycolipids.25,26

Figure 2. Mechanism of the sialylation reaction and expected products by sialyltransferase subtypes.

STs differ in their substrate specificity, tissue distribution and various biochemical
parameters. Enzymatic analysis conducted in vitro with recombinant enzyme revealed
that one linkage can be synthesised by multiple enzymes.27,28 Moreover, even though
eukaryotic STs share the same sugar donors, i.e. CMP-Neu5Ac (4), and recognize identical
acceptor substrates, they do not exhibit similar protein structure except for the four short and
conserved consensus sequences present in the catalytic domain.29,30 STs have been shown to
be primarily topologically restricted to trans cisternae and the trans Golgi network of the
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Table I. Nomenclature of the 20 human sialyltransferases (STs) described to-date.37-39
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Golgi apparatus, although catalytically active soluble forms can be generated in vivo by
proteolytic cleavage at the stem region, e.g. serum soluble ST6Gal I.31 The existence of cell
surface ST activity has also been reported for human monocyte-derived dendritic cells.32 Due
to the paucity of efficient selective, cell permeable inhibitors, much of the available
information regarding the importance of sialyltransferases has come from gene ablation in
mice.33,34 Recent research has led to further understanding of the biological involvement of
these enzymes in a host of disease states, further extending the array of potential therapeutic
applications of this target.35,36
C. Sialylation in Cancer
Elevated plasma levels of STs have been observed in cancer patients since the 70's, and
hypersialylation of cell surface proteins is now a well-established hallmark of cancer that
forms the basis of several diagnostic cancer markers.40-42 One such example is the
carbohydrate antigen CA19-9 for pancreatic cancer, which results from overexpression of
ST3Gal III, IV and VI leading to the production of large amounts of sialyl Lewisa (sLea).
Sialylated glycans have long been predicted as cell-type specific markers and critical
determinants in various cellular recognition processes (cell–cell recognition, adhesion, protein
targeting, blood coagulation, fertilization, and other biological events).43 They also play
significant roles in immune responses,44 inflammatory diseases, viral infection45,46 and tumour
proliferation,47 migration, and metastasis.48-50 STs have been described as “engines of selffuelling loops in cancer progression”.4,8,51 Hypersialylated integrins are believed to facilitate
cell migration in many different cancer types,52 such as colon,53,54 lung55,56 and ovarian
cancer.11 Aberrant sialylation at the non-reducing end of glycoproteins or glycolipids has been
shown to promote events involving abnormal stimuli in the interaction of neoplastic cells with
extracellular matrices.9 The biosynthesis of sialylated glycoprotein, mediated by ST6GalNAc
IV, was also reported on various kidney cancer cell lines.57 Before considering membrane
sialylated glycoproteins as a target for treating cancer, these molecular patterns are useful in
the prognosis of cancer58,59 and other diseases.60 Tumour cell migration and invasion are
regulated

by

sialylated
53,54

adrenocarcinomas

glycoforms
55,56

and lung,

of

integrins.

Specifically,

β1

in

colon

61

ST3Gal

where ST expression, in particular ST6Gal I,

I,62,63 ST3Gal III,48,61 ST3Gal IV,48,64 ST6GalNAc I65 and ST6GalNAc V66 are strongly
correlated with tumour invasiveness. This is also the case in numerous other cancers
including, bladder,63 breast,67 pancreatic,68 ovarian,11 gastro-intestinal69 cancers and
leukemia.70 (Fig. 3).
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Lung Cancer: Sialyl Lewis x (SLex) is a well-known tumour-associated antigen that is
found in elevated levels in lung cancer. It facilitates cell adhesion to the endothelium,
initiating the process of extravasation and metastasis. ST3Gal III, IV and VI enzymes play a
key role in the synthesis of SLex. In lung cancer, expression levels of both SLex and ST3Gal
III are inversely correlated with patient survival.71 Hypersialylation and increased expression
of SLex is also observed in the mucins of cystic fibrosis patients,72 while over-sialylation of
several other proteins including integrins has also been shown to enhance cell invasion in
ovarian, colon and lung cancer. ST3Gal I is not detected in normal human bronchial epithelial
cells, but is over-expressed in highly metastatic lung cancer cells such as A549 and CL1-5.56
Thus, inhibition of STs, in particular the ST3Gal subfamily, has emerged as a new target for
the treatment of early lung cancer, and to aid in understanding the progression to more
aggressive phenotypes.
Ovarian Cancer: Increased serum glycoprotein sialylation in a murine ovarian carcinoma
model has been found to correlate with inflammation and tumour progression, with increased
expression of ST3Gal I and ST6Gal I.73 The latter also regulates ovarian tumour cell survival
mechanisms74 and confers cisplatin resistance.75,76 CA125, the clinically used ovarian cancer
marker is a heavily glycosylated mucin (MUC16).62 Levels of sialyl-Tn antigen, expressed on
MUC16 in patients, is found to differ between endometriosis and ovarian cancer raising the
potential for its use in diagnosis, and evaluating the clinical stage, cytological grade, and
histological type of ovarian cancer.77
Breast Cancer: STs have been found to play a key role in breast cancer progression,
aggressiveness, metastasis and drug resistance. Recent studies in triple-negative breast cancer
patient-derived xenograft models treated with standard chemotherapy identified high levels of
the sialyl-glycolipid stage-specific embryonic antigen 4 (SSEA4). This treatment-resistant
breast cancer subpopulation also exhibited high expression of ST3Gal II, which is required for
the biosynthesis of SSEA4. This could be used as a potential predictive biomarker of poor
clinical outcomes in both breast and ovarian cancer patients treated with standard-care
genotoxic chemotherapy.78 Gene expression analysis coupled with functional analysis of
clinical samples has also identified ST6GalNAc V as a key mediator of breast cancer
metastasis to the brain. Atypical expression of this brain ST in breast cancer cells is thought to
facilitate their passage through the blood-brain barrier.79
The transmembrane tumour-associated glycoprotein Mucin 1 (MUC1) is aberrantly
glycosylated and overexpressed in a variety of epithelial cancers, where it is involved in
intracellular signal transduction pathways.80 A strong correlation between the expression of
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MUC1 and T antigen has been found in breast cancer tumours and breast cancer cell lines,
along

with

the

down-regulation

of

expression

of

core

2

β-1,6-N-

acetylglucosaminyltransferase (C2GnT1) and ST3Gal I.81 Cyclooxygenase-2 (COX-2) is
involved in the upregulation of ST3Gal I in MDA-MB-231 breast cancer cell lines leading to
increased sialylation of the ST3Gal I substrate, core 1 Gal-β-1,3-GalNAc, which can be
reversed using the COX-2 inhibitor celecoxib. Expression analysis of 74 primary breast
cancers showed a significant correlation between ST3Gal I and COX-2, indicating that
malignant characteristics of COX-2 expression may be related to tumour cell surface
sialylation.82 On a different note, cationic amphibian antibacterial peptides such as aurein 1.2
from the glands of the Litoria sp. frog and buforin IIb derived from the Asian toad Bufo
garagriozans, exploit the upregulation of sialylation in breast cancer cells (MX-1 and MCF-7)
to enhance their binding to sialylated N-, O-glycoproteins and gangliosides on the tumour cell
surface. This may contribute to their selective cancer toxicity. Buforin IIb also supressed
tumour growth in a MX-1 xenograft mouse model via induction of apoptosis and inhibition of
vascularization.83
Multiple Myeloma: High expression of ST3Gal VI has been identified in patients with
multiple myeloma (MM) and correlated to poor patient prognosis. Knockdown of ST3Gal VI
in MM cell lines MM1S and RPMI-8226 significantly reduced α-2,3-linked sialic acids on the
cell surface and reduced adhesion to bone marrow stromal cells and fibronectin. It further
inhibited transendothelial migration in vitro and reduced homing and engraftment, decreased
tumour burden and increased survival in vivo in a xenograft (SCID-Bg) mouse model.84
Leukemia and Glioma: Elevated mRNA levels of ST expression have been found to
positively correlate with a high risk of numerous cancers including paediatric leukemia, where
it has been suggested as a potential biomarker.85 In particular, cell surface sialylation is
emerging as an important feature of cancer cell multidrug resistance (MDR). Recently, the α2,8-sialyltransferases ST8Sia IV and ST8Sia VI were found to positively correlate with the
multidrug resistant phenotype in chronic myeloid leukemia (CML) cells, with ST8Sia IV
appearing to regulate the activity of PI3K/Akt signalling and P-gp expression.86,87
Overexpression of ST6GalNAcV, a ganglioside-specific α2,6-sialyltransferase, inhibits
glioma growth in vivo.88
Metastasis and MDR: Also of important consideration is metastasis, a major challenge in
the treatment of cancer, largely responsible for the high rate of cancer mortality. It is
emerging that molecules conferring drug resistance may also promote metastatic invasion.
This gives rise to the situation where metastatic disease is often more resistant to treatment.12

10

Cancerss where ST
T over-expression has been identtified as plaaying a crittical role in
n cancer
progresssion includee colon, pan
ncreatic andd prostate caancer.89

Figure 3. Gene alteration frequency of sialyltran
nsferase subty
ypes in varioous cancers.90

D. Centtral Nervou
us System
In contrrast to the aberrant hy
ypersialylati
tion that is a hallmark
k of many ccancers, a range
r
of
99
neurological and memory
m
dissorders inclluding Alzh
heimer’s,91-994 schizophr
hrenia,95-98 autism,
a

bipolar

1
disorder,100

depresssion,101

chhronic

strress102

and
d

alcoholiism,103

ex
xhibit

a

hyposiaalylation phenotype, along witth a conccomitant down
d
reguulation of various
sialyltraansferases. The
T ST8Siaa II gene haas been iden
ntified as a generalized
g
d susceptibillity gene
for psycchotic and mood disorders,104,105 as demonsstrated by McAuley
M
eet al. using genome
wide asssociation sttudy (GWA
AS).100 It haas also foun
nd to be asssociated wiith schizoph
hrenia in
Spanishh,106 Japaneese,107 and Chinese H an populatiions,95,96 along with aan associatiion with
autism,999 depressioon,101 and an
n increasedd risk of bip
polar spectru
um disorderr in specificc patient
and fam
milial cases.108,109 Inhib
bition of braain ST8Sia III has been found to lead to imp
pairment
of proceedural mem
mory in micce.110 Polyssialic acids were also reported too play a rolle in the
developpment of neurons,111 dendritic
d
ceell traffickiing112 and in the reseet of the circadian
c
clock.113
Thuus, the role and functio
on of reducced sialylation in memo
ory and neuurological disorders
d
will neeed to be furrther explorred alongsidde the deveelopment off small mollecule ST in
nhibitors
directedd at hypersiaalylation in
n diseases suuch as canccer. This alsso highlightts the imporrtance of

11

developing inhibitors that are selective for particular ST-subtypes, along with exploration of
targeted delivery of ST inhibitors directly to the tumour site.
E. Immune System, Inflammation and Others
Not only are STs an attractive target for cancer, they also present interesting applications in
other biological fields. The ST6Gal I sialyltransferase controls production of the Sia-α-2,6Gal-β-1,4-GlcNAc (Sia6LacNAc) trisaccharide, which is the ligand for the lectin CD22.
Binding of CD22 to Sia6LacNAc is implicated in regulating lymphocyte adhesion and
activation. Knock-out ST6Gal I mice were found to be viable and thus constitute a good
model for immunodepression, unlike CD22-deficient mice. Human sialoconjugates
incorporate the Neu5Ac form of Sia in constrast to Neu5Gc in mice, which is the main
difference.114 Notably, Sia6LacNAc-deficient mice displayed reduced serum IgM levels,
impaired B cell proliferation in response to IgM and CD40 crosslinking, and attenuated
antibody production to T-independent and T-dependent antigens. Deficiency of ST6Gal was
further found to alter phosphotyrosine accumulation during signal transduction from the B
lymphocyte antigen receptor. These studies reveal that the ST6Gal I sialyltransferase and
corresponding production of the Sia6LacNAc oligosaccharide are essential in promoting B
lymphocyte activation and immune function.34 Other disease states linked to a loss of ST gene
function include allergies, where deficiencies in ST6Gal I and ST3Gal III production in mice
is associated with enhanced allergic airway inflammation.115,116
Leukocytes are activated by binding to α-2,3-sialylated glycans and as a result, promotes
immunodepression due to a deficiency in the ST3Gal IV and VI enzymes.117 Leukocyte
accumulation was also shown to play a key role in atherosclerosis. In this field, ST3Gal-IV
has been identified as a promising target to reduce inflammatory leukocyte recruitment.
Studies by Doering et al. have shown ST3Gal-IV deficiency leads to reduced chemokine Ccl5
binding and Ccl5-induced flow arrest of myeloid cells, with marked reduction in the
inflammatory cell content of lesions in a mouse model of atherosclerosis.118 Rifat et al. also
investigated the influence of α-2,6-sialylated glycans on modulating the immunological
characteristics of neutrophil granulocytes.119
It has recently been shown that the immune killer cells’ activating receptors (NKG2D and
CD94) bind to α-2,3-sialylated, but not to α-2,6-sialylated N-glycans.120 Reduction in
cytotoxic T cells (CD8+) had been previously observed in mice after ablation of the ST3Gal I
gene. Sialylation clearly plays a key role in the immune system121 and thus ST inhibition is
also a promising therapeutic strategy against inflammation.122
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As avian influenza viruses preferentially use α-2,3-linked sialic acid as a receptor for
binding and entry into target cells, the selective inhibition of ST3Gal IV represents a potential
target for antiviral drug design.123 Another study identified the implication of ST6Gal I in the
infection of epithelial cells by viruses pdmH1N1 and H3N2.45 The myxoma virus was
previously shown to express α-2,3-STs and the resulting sialylated glycans promote
infection.124 Cells infected with HIV were found to contain higher levels of STs than healthy
cells.125 Sialylated glycoconjugates also constitute an important platform for host cell invasion
for parasites, such as infection with Toxoplasma parasites.126 The Gram-negative bacteria
Neisseria gonorrhoeae expresses an α-2,3-sialyltransferase (Lst) that scavenges sialic acid
from the host and uses it to sialylate the terminal lacto-N-neotetraose moiety of its
lipooligosaccharide (LOS). The resulting LOS sialylation is linked to serum resistance,
decreased antibody binding and decreased effectiveness of antimicrobial peptides, and thus
represents a potential new target for gonorrhea.127
ST6Gal I128,129 and ST8Sia I130 are both downregulated in the liver by chronic alcohol
consumption, along with reduced sialylation of serum transferrin and apolipoprotein E
(apoE).131 This affects its ability to bind to high density lipoprotein (HDL) leading to impaired
reversed cholesterol transport in alcoholics.132 In utero alcohol exposure is also found to alter
the expression and sialylation of NCAM isoforms during brain development in rats.133
Considerable alteration of ST8Sia II was observed in patients who received gastric
bypass surgery.134 GWAS was conducted on 693 participants and showed reduced expression
of the gene in ther liver and epididymal fat and revealed a significant association of the
ST8Sia II gene expression with weight loss.
The altered ST expression in a wide range of diseases highlights the critical and specific
role that different ST subtypes play in human biology. Furthermore, it illustrates the growing
need to develop selective inhibitors in order to further explore the intricate role of sialylation
in human disease.
F. Reviews
The design and development of potent small molecule ST inhibition was pioneered by
R.R. Schmidt and co-workers,135-138 almost two decades ago. The synthesis and biological
evaluation of ST inhibitors appearing at that time have been reviewed previously and
focussed on α-2,3-ST and α-2,6-ST subtypes.139-142 In the intervening years since the first
development of ST inhibitors, a rising number of biological and medical-related papers
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have appeared. This has expanded our understanding of the role of glycosylation in
various disorders, as well as the role of altered sialylation in disease, in particular cancer
and metastasis.143 For further reading in this area, there are several comprehensive reviews
on the biological function of sialic acids by Schauer & Kelm,16,144,145 Varki1,2,36,146 and
Crocker,147,148 and on the biological role of sialylation including reviews by Dall’Olio et
al.,3,51,149 Schultz et al.,8 Harduin-Lepers et al.,26-28 and Boons et al.150
Over the last decade, the therapeutic potential of targeting STs has appeared in part in
reviews focusing on GTs and altered glycosylation in cancer from Brooks et al.,151,152
Brown et al.,153 Compain & Partin,154 Gloster & Vocadlo,155 Hinou & Nishimura,156 Izumi
et al.,157 Kajimoto & Node,158 Roychoudhury & Pohl,159 Schnaar et al.160 and Zhou et
al.161 The last comprehensive small molecules review of ST inhibitors appeared over a
decade ago, before the first ST crystal structures were reported.139,140 In recent years,
along with the mounting evidence of the critical role of sialylation in cancer and growing
structural information on STs, several new potent ST inhibitors have been described.
These have been derived from various scaffolds and thus increasing the molecular
diversity of ST inhibitors in the literature. Herein, we review the latest highlights in the
design, development, biological evaluation and applications of ST inhibitors in both
medicinal chemistry and as important tools in chemical biology. This review draws on the
recent structural information available for STs, with a particular emphasis on the
challenges in the field, such as selectivity of inhibitors toward the different ST subtypes,
cell permeability, synthetic practicality, structure-based design and the emerging picture
of structure-activity relationships.

2. BIOLOGICAL ASSAYS
A. Enzyme Assays
A key challenge in the ST inhibitor field is the choice of biological assay employed to
evaluate the effectiveness of newly developed inhibitors. There are no commercially
available ST inhibitor screening assays at the time of writing, and very few commercial
sources of mammalian ST enzymes, those being rST3Gal I (EC 2.4.99.4) from Merck
(#566227) and hST6Gal I (EC 2.4.99.1) from Merck (#566223) and Roche (#07-012-250103). For this reason, most research groups clone, express and/or isolate their own ST
enzymes, which are used in either crude, partially purified or purified form.27,162-170 As
with all enzyme work, there are a wide range of enzymes used (e.g. predominantly human,
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rat, and bacterial STs) and a variety of assays employed (colorimetric, fluorescent,
radioactive, mass spectrometry and HPLC-based) to evaluate inhibitory activity, and this
should be considered when comparing biological results. Herein, a brief description of the
bioassays employed in the evaluation of ST inhibitors is included below, and in later
sections the assay utilised by each research group is highlighted for each study.
HPLC-based Assays: Earlier studies into sialyltransferases used asialofetuin or lactoN-tetraose as the acceptor moiety and
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C or 3H-labelled CMP-Neu5Ac171 as the donor

and the radioactive products were isolated by chromatography or precipitation.171-173 In
1998, RR Schmidt and co-workers introduced a HPLC-based assay using the pnitrophenyl glycoside of N-acetyllactosamine as a UV labelled acceptor, and this
continues to be one of the most widely used ST inhibition assays today.135 Recent
extensions of this method, include a continuous all-in-one HPLC-based assay that enables
the quantification of productive turnover, error hydrolysis and site selectivity of
sialyltransfer and donor substrate hydrolysis, with the potential for high-throughput
screening.174 Further HPLC-based assays include those reported by Kijahara et al. and
involve a combination of HPLC analysis with a fluorescent analytical technique based on
reacting sialic acid with 1,2-diamino-4,5-methylenedioxybenzene,175 or using 2-[(2pyridyl)aminoethyl-β-D-lactosamidine as a ST acceptor for potential use in fluorescent
assays.176
Fluorescence-based Assays: Rillahan et al. designed a fluorescence polarisation (FP)
assay enabling high-throughput screening of sialyl- and fucosyltransferases.177 The
methods employs a CMP-Neu5Ac derivative bearing a fluorescein isothiocyanate (FITC)
tag at the 9-position178 and asialofetuin as the acceptor. This technique has the advantage
of being applicable for various enzyme subtypes by using a versatile acceptor, however, it
does require the non-trivial preparation of the FITC-labelled CMP-Neu5Ac donor.
Kumagai et al. have reported a multi-enzyme system allowing the screening of potential
inhibitors against a wide variety of glycosyltransferases including glucosyl-, galactosyl-,
glucuronyl-, xylosyl-, fucosyl- and sialyltransferases.179 Three kinase enzymes are used in
order to provide glucose-6-phosphate (G6P) starting from the nucleoside monophosphate
resulting from the glycosylation reaction. G6P dehydrogenase converts then resazurin, in a
dose-dependant manner, to resorufin and the fluorescence of the solution is measured.
This method presents the advantage of allowing HTS of compound libraries.
MS-based Assays: Hosoguchi et al. designed a MS-based protocol suitable for HTS
of potential GT inhibitors. The authors monitored the inhibition rate by looking at the
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amount of glycosylated acceptor using MALDI-TOFMS.180 More recently, Preidl et al.
designed a binding affinity assay in which the dissociation constant was determined by
comparing the anisotropy changes in fluorescence polarisation.181 An alternative
technique consists in immobilising the acceptor sugar on a plate or a cellulose membrane.
This method was described using N-acetyllactosamine182 or trisialyl lactoside (GT3) by
click-chemistry.183

Other

assays

using

multi-enzyme

systems

combined

with

spectrophotometry53,184 or colorimetry185 have also been reported.
B. Cell-based Assays
Altered sialylation of the cell surface as a result of ST inhibition is expected to affect
metastatic cell behaviours such as invasion, adhesion and migration, rather than cell viability.
For this reason, classic cytotoxicity tests such as MTT and MTS assays have shown very little
to no toxicity for a range of ST inhibitors, which greatly enhances their drug development
potential.56,186-188 Thus, the most prevalent assays in this area are those that measure cell
invasion;189 cell migration using Transwell chamber migration assays;55,186 cell adhesion to
plates coated in collagen IV, fibronectin or laminin,55,56,189,190 along with traditional wound
healing assays.55,186,191 Further anti-metastasis assays include those that assess activation of
integrins and downstream mediators of integrin signalling, such as FAK (focal adhesion
kinase),56,186 and PI3K/Akt signalling via Western blot analysis.87 Other assays looking at the
functional consequences of altered cell surface sialylation include examining effects on
selectin-mediated leukocyte rolling in HL-60 cells and MS analysis of the N-glycans from
inhibitor-treated cells as described by Rillahan et al,187 as well as effects on NCAM
polysialylation via ST8Sia inhibition.188,192 Table II shows some of the cancer cell lines used
in cell-based evaluation of ST inhibition.
Other cell-based methods of determining the extent of ST inhibition include flow cytometry
analysis of cell surface sialylation using biotinylated lectins. For example M. amurensis lectin
II, which is specific for α-2,3-linked sialic acid and Sambucus nigra lectin, which is specific
for α-2,6-linked sialic acid.55,56,181,187,189
Lectin affinity has also been used to precipitate lectin/sialylated protein complexes out of cell
lysates, followed by cleavage of the complex and Western blot analysis of the sialylated
proteins.55,56 Cellular uptake of labelled ST inhibitors has been investigated using a range of
cell staining techniques and confocal microscopy, successfully demonstrating the cell
permeability of a range of ST inhibitors.56,181
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Table II. Ccell lines used in sialyltransferase inhibition studies.
Cancer type
Breast cancer

Colon
adrenocarcinoma

ST type
ST3/6Gal I

Cell line
MCF-7
MDA-MB-231

indirect

NL-17

ST8Sia II & IV

HL-60

Pheochromocyta
Leukemia,
Lymphoma

ST8Sia II & IV
ST3Gal Ia
ST6Gal I

PC-12
HL-60, Ramos cells

Lung cancer

ST3/6Gal I

Melanoma

ST3Gal I

CL1-0, CL1-5, CL15F4, A549, H1299,
BES-6b
B16F10 (murine)

Neuroblastoma

ST8Sia II

SH-SY5Y

ST3Gal II,
ST6Gal I

B35, CHO

a
b

Analysis
Viability, adhesion, migration,
invasion, flow cytometry, lectin
affinity, FAK
Cell proliferation, wound healing
assay
Cell attachment, cell-induced platelet
aggregation
Immunoblotting, quantitative RTPCR
Flow cytometry, glycan profiling,
lectin affinity, leukocyte rolling
assays
Viability, adhesion, migration, flow
cytometry, in vivo lung metastasis
assay
Adhesion, migration, invasion, flow
cytometry, in vivo lung metastasis
assay
Migration, flow cytometry, Western
blot
Flow cytometry, immunoblotting

Reference
Chang, 2011185
Fu, 2015190
Kijima-Suda, 1988189
Horstkorte, 2004191
Rillahan, 2012186
Chiang, 201056
Chen, 201155
Chang, 2006188
Al-Saraireh, 2013187
Preidl, 2014180

Also ST3Gal II, IV, VI.
Normal cell line.

In vivo evaluation of ST inhibitors in a range of experimental animal xenograft models
has been reported. These include inhibition of lung metastasis in BALB/c mice induced by
injection with A549 human lung adenocarcinoma epithelial cells;56 B16F10 human melanoma
cells;189 murine colon adenocarcinoma 26 sublines of high (NL-17) and low (NL-44)
metastatic potential;193 or highly metastatic murine 4T1-Luc breast cancer cells.55 A multidrug
resistant (MDR) leukemia xenograft model in mice injected with K562 (human
erythromyeloblastoid leukemia) and K562/ADR (adriamycin-resistant) cells has been
described by Zhang et al.87 In earlier work, a liver metastasis assay was used to assess the role
of sialyation in hepatic tumour growth in athymic male Swiss nude mice injected with human
colorectal cells.194 Zebrafish are an emerging live whole animal model for early
pharmacological assessment of safety and toxicity in drug development,195 and have been
used for examining the expression and evolution of ST8Sia III196 and its link to neuronal
migration.197 Mapping of the glycome and glycosyltransferases of zebrafish liver cells
provides a useful tool for future glycosylation studies in this model system.198

3. CRYSTALLOGRAPHIC DATA
As a result of the tremendous therapeutic potential associated with STs, the design and
development of selective ST inhibitors is a promising new challenge. Efforts have been made
to identity and understand the structural differences between the different ST subtypes.

17

Accordingly, the crystal structures are obtained with an additive co-crystallized with the
enzyme, such as CMP (5), CDP (6), the inhibitor CMP-3F-Neu5Ac199 (7) or several different
sugars, including oligosaccharides. The presence of these compounds provides information
about the location of the active site.
Bacteria were found to be a good source for STs. From Campylobacter jejuni, Cst-I was
isolated and found to promote α-2,3-sialyl patterns200 and Cst-II, which is multifunctional,
catalyses both α-2,3- and α-2,8-sialylation.201 Crystallization of PM0188, an α-2,6-ST from
Pasteurella multosida, has been reported by Kim et al.202,203 However, PM0188 presents very
low sequence homology to other sialyltransferase families. From the same bacteria,
24PmST1 was also examined. The enzyme shows α-2,3-ST, α-2,6-ST, sialidase and transsialidase acitivity.204,205 Additional mutation provided another enzyme, derived from PM0188,
with inverted substrate selectivity, i.e. from α-2,3 to α-2,6. The crystal structure of this mutant
enzyme P7H-M117A, expressed in Pasteurella dagmatis was reported by Schmöelzer et al.206
Ni and Sugiarto et al. successfully generated a mutant version of 24PmST1 and described
the crystal structure of the name D141N and M144D, respectively.207 M144D showed
significantly decreased sialidase activity. In a similar approach, the crystal structure of the
mutant bifunctional α-2,3-ST and α-2,6-ST 29NST was obtained from the bacterias
Neisseria meningitides. 16psp26ST is a truncated form of JT-ISH-224, mono-functional βgalactoside α-2,6-ST, cloned from Photobacterium phosphoreum and its crystal structure was
reported by Kakuta et al.208 Npp23ST, also a truncated form of JT-ISH-224, was later
crystalized by Iwatani.209 Huynh later reported the structures of 15Pd2,6ST(N) and
112Pd2,6ST(N) which also are α-2,6-STs from Photobacterium damselae.210
The first mammalian ST crystal structure was reported by Rao et al.211 The crystalized
enzyme is a porcine ST3Gal I variant and presents approximately 85% homology with the
corresponding human ST. From this data, the authors later proposed a mode of binding for the
donor CMP-Neu5Ac and the acceptor sugar.212 More recently, both rat213 and human214
ST6Gal I crystal structures were also reported. The latest human crystal structure reported is
ST8Sia III (Fig. 4).215
The crystallographic data provides insight on the mode of action of STs and allows the use of
computational tools to assist structure-based design of inhibitors. Bacterial and mammalian
STs crystal structures are summarised in table III. All reported PDB files are available on the
RCSB Protein Data Bank website (www.rcsb.org).
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Table III. Examples of reported crystallographic data for ST substypes and their corresponding PDB
file names.
Table III. Examples of reported crystallographic data for ST substypes and their corresponding PDB file names.
Enzyme
Organism
PDB file
Reference
Cst-I
Campylobacter jejuni
2P2V,a 2P56
Chiu, 2007199
a
b
Cst-II
Campylobacter jejuni
1RO7 ;1RO8
Chiu, 2004200
Cst-II
Campylobacter jejuni
2X61,b,h 2X62,b 2X63b
Lee, 2011215
PM0188
Pasteurella multocida
2IY7,a 2IY8,a,c 2C83, 2C84b
Kim, 2006201 202
Ni, 2006204
Pasteurella multocida
2EX0, 2EX1b
24PmST1
Ni, 2007203
Pasteurella multocida
2IHJ,a 2IHK,a 2IHZ,a,c 2ILV,b,c
24PmST1
b
b
D141N
Pasteurella multocida
2IIB, 2II6
Ni, 2006
M144D
Pasteurella multocida
3S44b
Sugiarto, 2012206
b
b
P7H-M117A
Pasteurella dagmatis
4V2U, 4V38, 4V39, 4V3B, 4V3C
Schmöelzer, 2015205
b
d
a
Lin, 2011216
Neisseria meningitides
2YK4, 2YK5, 2YK6, 2YK7
29NST
JT-ISH-224
Photobacterium phosphoreum
2Z4Tb,c
Kakuta, 2008207
b
Iwatani, 2009208
Photobacterium phosphoreum
2ZWI
Npp23ST
a
Huynh, 2014209
Photobacterium damselae
4R83, 4R84
15Pd2,6ST(N)
Photobacterium damselae
4R9V
Huynh, 2014209
112Pd2,6ST(N)
ST3Gal I
Sus scrofa (pig)
2WML, 2WNB,b,e 2WNFe
Rao, 2009210
ST6Gal I
Rattus norvegicus (rat)
4MPS
Meng, 2013212
ST6Gal I
Homo sapiens (human)
4JS1,f 4JS2b
Kuhn, 2013213
d
g
a,h
ST8Sia III
Homo sapiens (human)
5BO6, 5BO7, 5BO8, 5BO9
Volkers, 2015214
The crystal structure of the enzyme was obtained co-crystalized with a) CMP-3F-Neu5Ac 7, b) CMP 5, c)
Sia6SLacNAc d) lactose, e) CDP 6, f) 2-nitrophenyl-Galβ1,3GalNAc, g) Cytidine, and h) CTP.
216
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4. SIALYLTRANSFERASE INHIBITORS
Promising in vivo results endow ST inhibitors with a considerable interest in their therapeutic
potential, particularly in the area of cancer. A large number of compounds have been
described to date. They belong to different classes of molecules and scaffolds and recent
discoveries based on natural products or high throughput screening provide even more
molecular diversity. Consequently, drawing a structure-activity relationship model is a
difficult task.
A. Inhibitors from Nature
Although natural products were used for thousands of years, their isolation and application
still play critical roles in modern drug development, especially for antibacterial and
antitumour agents. Soyasaponin I (8) from soybean is a rigid pentacyclic system with a
trisaccharide component that showed significant inhibition of ST3Gal in vivo (Ki = 2.1 µM)
(Fig. 5). Along with good cell permeability, this compound exhibited properties relating to
invasive/metastatic behaviours of cancer cell lines.228 Soyasaponin I was also found to
specifically inhibit the expression of α-2,3-linked sialic acids without affecting other glycans
on murine melanoma cells.189 Various steroidal compounds have been reported to exert
inhibitory effects on ST3Gal I among them, epiandrosterone succinyl ester, isolated from the
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parasite Schistosoma japonica and known as a glutathione S-transferase inhibitor,229 had an
IC50 value of 350 µM.189 From this example, efforts to provide new ST3Gal I inhibitors based
on aminoacids esters (IC50 = 480 µM) or phosphate (IC50 = 400 µM) conjugates of
epiandrosterone were undertaken, however the compounds showed lower potency than the
parent compound.230
Another steroidal derivative that has attracted attention is lithocholic acid (9) (Fig. 5).
This compound has been shown to inhibit ST3Gal I (IC50 = 21 µM). Consequently, a series of
lithocholic acid derivatives were designed by Chang et al. and their activities evaluated on rat
ST3Gal,230 wherein, succinic and aspartic acids conjugates gave a similar range of affinity
with the enzyme. On the other hand, the reduction of the carboxylic acid group to the
corresponding alcohol significantly decreased activity (IC50 = 351 µM). The same effect was
observed for its phosphorylated analogue (IC50 > 100 µM). The oxidation of the secondary
alcohol to a ketone also decreased the activity (IC50 = 139 µM). Nevertheless, the conversion
of the primary alcohol derivative to the azide counterpart gave way to a series of 1,4disubstitued triazoles, conveniently obtained by click chemistry. In general, compounds
bearing an acidic carboxylic group attached to the side chain generally presented increased
activity when compared to the analogous alcohol. The most active lithocholic acid derivative,
the L-Asp compound (10) (Fig. 5), was the object of further biological evaluation. The socalled Lith-O-Asp derivative was found to inhibit migration and invasion in various cancer
cell lines and showed inhibitory activity towards human umbilical vein endothelial cells.55 By
decreasing the sialylation of integrin-β1 and consequently inhibiting the expression of
phospho-FAK, phosphopaxillin and matrix metalloproteases, Lith-O-Asp suppressed cancer
cell metastasis. This compound was later the object of further clinical studies which suggest a
promising potential for metastasis treatment.
Other lithocholic acid derivatives showed encouraging results from pre-clinical
experiments. AL-10 (11) (Fig. 5), which is structurally related to Lith-O-Asp, exhibited
inhibition of ST3Gal I (IC50 = 0.88 µM) and ST6Gal I (IC50 = 1.50 µM) in enzyme
inhibition assays.56 As observed with Lith-O-Asp, the sialylation of α5, αv and β1
integrins was repressed. As a result, adhesiveness to fibronectin and laminin was reduced,
leading to decreased migratory activity of the metastaic cells. The test of the
antimetastatic effect of AL-10 in vivo revealed a 40% reduction of lung metastasis in
serum biochemical assays. More recently, further derivatives have been prepared based on
the encouraging results observed with the Lith-O-amino acid compounds.191 Therefore,
short peptidic units were attached to the 3-O-position of the steroid moiety. All these
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compounds were tested against ST3Gal I and some of the most potent were also evaluated
against ST6Gal I. Most compounds showed moderate activity against the enzymes in the
low micromolar range (12-16) and inhibited the migation of highly metastatic cancer cell
lines (MDA-MB-231) (Fig. 5).
Some examples of lithocholic acid derivatives exhibiting ST inhibition are
commercially available, such as lithocholic acid (CAS: 434-13-9), lithocholylglycine
(CAS: 474-74-8) and lithocholyltaurine (CAS: 516-90-5).
However, the binding site for the lithocholic acid derivative is not clearly defined and
could possibly be allosteric, these compounds shown to exhibit a wide range of off-target
activities including inhibition of the nuclear pregnane X receptor,231 antagonism of the
Eph-ephrin system,232,233 activation of Vitamin D receptor,234 agonism of thee TGR5
receptor,235 interaction with acetylcholine receptors236 and increased invasiveness by upregulating urokinase-type plasminogen activator receptor in colon cancer.237
Three metabolites isolated from the fungus Stachybotrys cylindrospora have been
reported as ST inhibitors. Lin et al., evaluated the activity of these spirocyclic drimanes
(Mer-NF5003F or stachybotrydial (17), and the lactone counterpart (18) towards ST3Gal I,
ST3Gal III and ST6Gal I using a radiolabelled assay162 as well as some fucosyltransferases
and galactosyltransferases (Fig. 6).238 All compounds showed affinity against the enzyme in
the low micromolar range as well as some selectivity for ST6Gal I. These terpenes were also
shown to exhibit a range of off-target effects including myo-inositol monophosphatase
inhibition,239 activation of Glu-plasminogen,240 antiviral and antiplasmodial241 as well as
pancreatic cholesterol esterase inhibition.242
Marine metabolites currently constitute an attractive source of new bioactive structures in
medicinal chemistry. The Taiwanese cyanobacteria Lyngbya Majuscula was found to produce
two fatty amides, isomalyngamide A and A-1 (19), which share a common 4-methoxypyrrol2(5H)-one scaffold (Fig. 5). The activity of these compounds was examined by Chang et al.
against proliferation and migration of metastatic human breast cancer cells (MCF-7 and
MDA-MB-231).186 The study included ST3Gal I inhibition measurement of the natural
products and their synthetic analogues using Schmidt’s HPLC-based assay.135
Isomalyngamides themselves show high inhibitory activity (IC50 = 77.2 µM and 65.7 µM
respectively) and the synthetic analogues (20) displayed even greater affinity (Fig. 5). Once
again, the authors suggest that the hypersialylation of β1-integrin may play a key role in
cancer migration processes.
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Figure 5. Sialyltransferase inhibitors from Nature.
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Several flavonoids exhibiting inhibition of STs have been recently reported by Hidari et
al.243 The radiolabelled assays,172,173 performed using both rat, human ST6Gal I and rat
ST3Gal I, revealed potent inhibitory activity for some of these compounds, while
hydrogenation of the pyranone ring led to loss of the activity. Succesful inhibition was
obtained with derivatives bearing a 3’,4’,5’-trihydroxyphenyl moiety (21-23) (Fig. 5). The
authors also suggest that glucosylation at the 6-position of the chromene ring may affect
specific-linkage inhibition of sialylation. Kinetic properties of these compounds were also
examined for ST6Gal I and revealed mixed inhibition profiles. Epigallocatechin gallate (24),
was previously shown to moderately inhibit rat brain ST3Gal I (EC 2.4.99.4), IC50 = 2.7
µM.244 This compound also inhibits fucosyltransferases in a similar order of potency.
B. Inhibitors Discovered from High Throughput Screening
Paulson et al. discovered new small molecules with high ST inhibitory activity using
high-throughput screening (HTS) of compound libraries.177 The molecules were evaluated
against porcine ST3Gal I, rat ST3Gal III, human ST6Gal I as well as human FUT6 and human
FUT7. This study includes mildly to very selective inhibitors (25-26) of ST3Gal III with high
affinity for the enzyme (IC50 = 1.7 µM) whereas the activity towards the other enzymes
ST3Gal I, ST6Gal I, FUT6 and FUT7 was negligible (Fig. 6). In addition, this compound was
found to be competitive with the natural donor substrate site.
High throughput screening of synthetic combinatorial libraries identified a new
hexapeptide inhibitor for ST3Gal I.245 Comparison of 114 different peptides (NH2X6X5X4X3X2X1) revealed that the terminal tryptophan residue (X1) was optimal, and glycine,
asparagine and arginine were less active. Tryptophan also appeared to be ideal at the three
following positions (X2, X3, and X4). The authors determined a Ki value of 8.8 µM for
hexapeptide NH2-GNWWWW (27), showing the most promising activity (Fig. 6). Kinetic
studies revealed this peptide to be a noncompetitive inhibitor of ST3Gal I. This compound
also exhibits inhibitory activity toward ST6GalNAc I and ST6GalNAc III.
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Figure 6. Sialyltransferase inhibitors discovered by high throughput screening.

Not only organic molecules can afford biological activity, but some polyoxomolybdates
have also been indentified as antitumour,246-248 antibacterial249 or antiviral agents.250 In order
to elucidate the mechanism of action of such complexes, Seko et al. explored the inhibitory
activity and selectivity of molybdate, tungstate and vanadate compounds towards a few
glycosyltransferases including mutated ST3Gal I and ST3Gal II.251 IC50 values of the
tungstates for ST3Gal I are potent (0.1-1 nM), ten fold lower than for ST3Gal III, ST6Gal I
and ST6GalNAc I. The other enzymes evaluated (β4Gal-T1, β3Gn-T2 and FUT3) were
inhibited only weakly or not at all. The vanadate-type compounds appeared to be more
specific towards ST subtypes than the tungsten-type derivatives.
C. Acceptor Analogue Inhibitors
Since the early modified disaccharides reported by Hashimoto’s group,252 a number of
different types of acceptor-analogue have been designed. N-acetyl-β-lactosamide has been
modified at the 6-position of the galactose residue, including deoxy (28), mercapto (29),
O-THP (30) and dissulfide (31) groups. These compounds afforded modest inhibitory
activity against rat ST6Gal I (Ki = 0.76 to 4.14 mM) and revealed that the 6’-OH group is not
essential for substrate binding.253 Okazaki et al. also reported methyl 5a’-carba-β-lactoside
derivatives (32-34) and tested them against rat ST3Gal I and ST6Gal I.254 The inhibitors
display some activity in the µM range and up to 1/2.8 selectivity ratio was observed. These
inhibitors exhibit only modest activity (Fig. 7). To our knowledge, no acceptor-analogue
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inhibitors were reported recently and the existing compounds have been previousy
reviewed.142

Figure 7. Sialyltransferase inhibitors based on acceptor analogues.

D. Cytidine-based Inhibitors
The structure of CMP-Neu5Ac 4 can be divided into three major fragments: the nucleoside
fragment, the sialic acid fragment and the phosphodiester linker.
Cytidine fragment: Over the last decade, several research groups focused on the design
of donor analogue inhibitors. Prevention of glycosyl transfer is mediated by binding in the
active site of the enzyme in competition with the natural glycosyl donor CMP-Neu5Ac (4).
These inhibitors generally contain a cytidine component which was found to be essential for
binding to the enzyme.255 CMP 5, CDP 6 and CTP were shown to exhibit inhibition (Ki = 16
to 50 µM against rat liver ST6Gal I, Ki = 10 µM competitive inhibition against ST8Sia II).188
Uracil and resorcinol derivatives show reduced affinity for ST6Gals255 while being noncompetitive.256 Adenine derivatives showed very low if any activity against ST3Gal I257 and
ST6Gal I.256 5-Methylcytosine derivatives showed selectivity for ST8Sia258 and the 5-FU
analogue, for which inhibitory activity was twice as potent.259
Substitutions and alterations of the ribose fragment were also explored and revealed some
differences between the ST subtypes. 2’-O-Methyl-CMP promoted 84% inhibition at 250 µM
against ST3Gal-III and no inhibition against ST6Gal I (CMP exhibited 67% and 49%
inhibition respectively at the same concentration).258 This result suggests that the environment

26

in the active site is significantly different from one enzyme subtype to another. In addition,
this confirms that the empty pocket neighbouring the 2’-hydroxyl group, as observed on the
pST3Gal I crystal structures (PDB ID: 2WNB), provides an avenue for selective ligands. 2’Deoxycytidine was evaluated against human serum ST activity and showed very mild
inhibition, ranging from 5.9% at 100 µM to 32.5% at 1 mM.256 Ara-CMP and ara-CTP
exhibited mild competitive inhibition against ST6Gal I (Ki = 1.10 mM and 0.50 mM
respectively).256 Replacement of the furan ring by a 1,3-dioxolane moiety gave inactive
compounds (IC50 > 100 µM).257 In a different approach, Tanaka et al. explored the
replacement of the entire ribose moiety by a peptidic scaffold.260 The general outcome of
these studies led to the consideration of cytidine as essential for the activity on ST6Gal I.255
Most cytidine nucleotides act as competitive ST6Gal inhibitors.256 Other examples bearing a
5FU moiety exhibit modest activity such as the sialic acid-nucleoside conjugate KI-8110 (35)
(Fig. 8).261 This compound was preliminarily considered a ST inhibitor by indirect evidence,
observing diminution of sialylation of the cell surface of treated cells. However, it was later
found to inhibit CMP-Neu5Ac transport into the Golgi.262
Linker: An interesting feature in KI-8110 35 is the fact that the compound does not bear
any group mimicking the native phosphate linker. The phosphate linker between the cytidine
and sialic acid fragments appears to contribute largely to the binding to the active site of the
enzyme. A few isosteric replacements for the phosphate group were investigated, including
phosphoramidate analogues prepared stereoselectively.263 The resulting inhibitors exhibited
moderate activity in the low micromolar range. Replacement of the native phosphate linker
by phosphonate esters was also evaluated. When the phosphonate group is directly linked
to the anomeric centre of the sialic acid fragment, weak inhibition is observed (Ki = 250780 µM against rat liver ST6Gal I).137 However moderate to weak activity is observed
when tethered via an ethylene linker (IC50 = 47-3300 µM against rat ST3Gal I and 3404300 µM against rat ST6Gal I).264 By using simplified molecular tools, Lee et al. prepared a
series of 5’-triazolonucleosides to evaluate their activity on rat liver α-2,3-ST.257 In agreement
with previous observations, the adenine derivatives failed to prove significant inhibition.
Among the cytidine based molecules, only compound 36 showed significant activity (IC50 =
37.5 µM). Interestingly, the presence of a phenyl group seems to be a determinant factor,
presenting a 2-fold improvement over the cyclopentyl counterpart 37 (44% inhibition at 300
µM) (Fig 8). In order to increase the hydrophobicity of the compounds and improve their cell
permeability, Kumar et al. explored CMP-Neu5Ac analogues bearing non-charged linkers
instead of the phosphate group.265 Three neutral patterns were explored: triazole (38),
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sulphonamide and amide. Further modifications on the sialyl moiety also included 2-deoxy2,3-dehydro-acetylneuraminic acid derivatives or aromatic rings. The inhibitory activity of
these compounds was evaluated against the bacteria C. jejuni Cst 06, using a HPLC-based
technique,135 and relatively low inhibition observed (10.7-79.4% at 500 µM). The 5’-triazole
nucleoside analogs, obtained by click chemistry, appeared to be competitive inhibitors. On the
other hand, two of the most active compounds (39-40) showed non-competitive inhibition,
suggesting the nitro group could play a role in the binding with the active site of the enzyme
(Fig. 8).

Figure 8. Structure of CMP-Neu5Ac derivatives with a modified linker.

Sugar fragment: The most efficient modifications appear on the sialyl residue. The nonsialyl framework CMP-quinic acid derivative, for example, displays practically identical Ki
values (44 µM against rat liver α-2,6-ST) to CMP-Neu5Ac 4 (Ki = 46 µM against rat liver α2,6-ST). For this purpose, the use of sialyl mimetics, which do not possess glycosidic bonds,
are suitable to prevent glycosyl transfer. Corresponding phosphonates (sialic acid mimicked
by a phosphonate or carboxylate linked via a non-hydrolysable spacer) were less potent
inhibitors. Phosphoramidates containing amino acid as sialyl mimetics (R-CH(CO2H)NHCMP) were also found to possess low inhibition towards ST3Gal and ST6Gal. Based on this
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knowledge, Schmidt’s group prepared a number of CMP-Neu5Ac analogues including
cyclohexanone moieties, acetylaminocyclohexane and their hydroxylated derivatives.266
Inspired by 3-fluorosialic acid as a neuraminidase inhibitor, Burkart et al. prepared CMP3F-Neu5Ac (7) via the phosphoramidate route.199 The same compound was also synthesised
using a chemoenzymatic strategy.216 CMP-3F-Neu5Ac inhibits ST6Gal I with Ki = 5.7 µM
and became a reference compound for inhibition assays. It was also co-crystalised with various
ST subtype, enabling identification of the active site (cf section 3).
In analogy to some inhibitors mimicking the transition-state bearing a bicyclo[3.1.0]hex2-ene moiety firstly described by Sun,267 Niwayama et al. developed diacid derivatives.268
The intention of such compounds undergoes a Meinwald rearrangement and the
stereospecificity is controlled by the use of pig liver esterase. The study provided four new
compounds, however assessment of their biological activity has not been reported.
Click chemistry is an elegant way to obtain libraries of highly functionalized compounds.
Using this methodology, Hosoguchi et al. reported a library of over 70 donor-based inhibitors
obtained by click reactions between 5’-azidocytidine and 36 commercially available
alkynes.180 The library is comprised of CMP-Neu5Ac analogues bearing a functionalized
triazole group at the 5 or 9-position of the sialyl moiety, respectively, assuming that these
modifications should not significantly affect the binding of the compounds in the active site of
the enzyme. The ST inhibition was determined using a MALDI-TOF MS-based HTS towards
ST3Gal III, ST6Gal I as well as α-1,6-FucT. These molecules display inhibitory profiles
toward the considered enzyme subtypes, ranging from 15 to 80 %, and even selectivity,
providing important information about the donor binding sites. The authors suggest that a
flexible loop in mammalian ST6Gal I might be different from those of ST3Gal III, even if
both share the same natural donor. The derivatives of the 9-modified library did not show
significant inhibitory activity, but were recognized as the substrate by the enzymes.
Compound 41 of the 5-modified library show potent inhibitory activity, whereby the
compound showed a significant selectivity, with strong non-competitive inhibition of ST3Gal
III (IC50 = 8.2 µM) over moderate competitive inhibition of ST6Gal I (IC50 = 125 µM) (Fig.
9). This result clearly demonstrates that the sugar transfer reaction is not disturbed by bulky
substitutions at the 5- or 9-position. It is also interesting to note that the most active
compounds in this library bear a steroidal moiety.
In continuation of previous work initiated by Schmidt’s group,135 extended libraries of
compounds have been synthesized providing active molecules at the submicromolar level on
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rST6Gal I. Among them, the first series was obtained by coupling cytidine with
functionalized α-hydroxyphosphonates, using the phosphoramidite route, activated with 1Htetrazole.266 The α-hydroxyphosphonate portion of the molecule bears a substituted benzene
ring, naphthalene of heterocycle269 and this building block was prepared using an asymmetric
synthetic pathway to promote optically pure synthon. This study indicates that the
configuration of the stereogenic centre attached to the phosphonate group has little influence
on the activity. On the other hand, no relevant conclusion evolves from the electronic
influence (donating of withdrawing) of the substituents present on the aromatic ring. However,
compound 42, bearing a 3-phenoxy group, presents a significantly increased affinity with the
enzyme (Fig. 9). This relevant enhancement of the affinity implies the presence of aromatic
aminoacids in the active site and the phenoxy group would thus promote an aromatic-aromatic
interaction with them. Phosphoramidate analogues have been prepared stereoselectively,263
with the (R) compound found to exhibit competitive inhibitory activity (Ki = 68 ± 24 µM)
however less potent than their phosphodiester counterpart.
Building on the potent scaffold 42, fluorescent probes were designed.181 Binding affinity
of the compounds were evaluated using a fluorescence polarisation assay against rST3Gal II,
hST6Gal I and bacterial PmST1 and Pd2,6ST(N). The probes were found to exhibit activity in
the low nanomolar range. A fluorescein based tag was attached to the 3- or 4-position of the
aromatic ring (43) using an acetamide linker and the corresponding analogues bearing a
glycine spacer were also prepared (Fig. 14). The use of cell-based assays shed light on the
permeability of the probe and provided evidence that the compounds reached locations inside
the cell surrounding the nuclei and possibly to the trans-Golgi network. Other assays assessed
the inhibition of sialylation in two cell lines, Chinese Hamster Ovary cells and B35
neuroblastoma cells. The authors suggest that a putative membrane receptor may play a key
role in the vesicular uptake of the compounds.
Li et al. reported potent cyclopentane-based CMP-Neu5Ac analogues.270 These transition
state inhibitors also bear a CMP fragment and an α-hydroxyphosphonate moiety and the sialic
acid fragment was replaced by a five membered ring. In agreement with other inhibitors
described above, the non-substituted cyclopentyl counterpart 44 displays weaker activity than
the corresponding phenyl analogue. The design of more elaborate sugar mimic fragments was
inspired by the structurally related sialidase inhibitor peramivir, which provided the most
potent examples 45-47 (Fig. 9).
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Figure 9. Sialyltransferase inhibitors bearing a modified sialic acid fragment.

E. Bisubstrate Analogues
Bisubstrate analogues constitute an interesting rational design approach for enzyme inhibition.
Considering that the major difference between ST subtypes occurs primarily in the acceptor
site, two main strategies have been explored for the design of bisubstrate analogues. These
include a lactose unit tethered to an entirely intact CMP-Neu5Ac, or a CMP-KDN, moiety at
the 3-axial position of the sialic acid residue.271 Thioethers and alkanedithiols (48) were used
as a linker to attach both fragments together (Fig. 10). All compounds were tested against rat
ST3Gal I and ST6Gal I. The Neu5Ac derivatives were consistently more potent than the
corresponding KDN counterparts and all of them exhibited modest inhibition in the low
micromolar range.
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Furthermore, a structure-activity relationship study also evaluated a bisubstrate analogue,
prepared by Izumi’s group and showed only weak inhibitory activity against recombinant
rat ST3Gal I (IC50 = 1.3 mM) and ST6Gal I (IC50 = 2.4 mM, 49, Fig. 10).264 This series
present two key structural features. The linker was replaced by a phosphonate group which is
no longer a leaving group and the donor and acceptor fragments are tethered with a
phosphodiester moiety. The potential of bisubstrate ST inhibitors remains to be realised.

Figure 10. Structures of bisubstrate sialyltransferase inhibitors.

F. Metabolic Inhibitors
Paulson’s group created two fluorinated monosaccharide analogues as metabolic ST
inhibitors.187 The strategy uses a modified bioprecusor of CMP-Neu5Ac to obtain the
inhibitor inside the cell, synthetised in situ by the locally available enzymatic artillery, as
previously observed with other glycosyltransferases.272 For this purpose, peracetylated 3fluorosialic acids (both separated diastereoisomeres 50 and 51) were able to cross the cell
membrane and, after ‘deprotection’ by cytosolic esterases, get through salvage pathways to
provide the potent donor-analogous inhibitor CMP-3Fax-Neu5Ac (7) (Ki = 5.7 µM), first
described by Burkart199 or the corresponding equatorial counterpart 52 (Fig. 11). The presence
of a fluorine atom at the 3-position of the sialic acid prevents turnover by inductively
destabilizing the oxocarbenium ion-like transition state of the catalytic process.273
Furthermore, the structural similarity of these compounds with the natural donors shuts down
the de novo synthesis of CMP-Neu5Ac because of feedback loops in these pathways, induced
by their accumulation. As long as evidence for Golgi localization of CMP-3F-Neu5Ac is not
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clearly established, the inhibition of sialylation is thus thought to result from substrate
depletion.
Although highly effective in vitro, subsequent in vivo studies by Paulson involving
systemic blockade of sialyation in mice revealed the limitations of using global sialylation
inhibitors such as P-3Fax-NeuAc in vivo due to renal failure. Given the crucial role of
sialylation in such a myriad of biological processes and particular the high level of expression
in liver and kidney tissue, this is not unexpected. However, as stated by the authors, these
results highlight the importance of developing selective, small molecule ST inhibitors for
therapeutic purposes, while metabolic inhibitors will still have a crucial role to play as
biological tools in uncovering more about the role of sialylation in disease progression.274

Figure 11. Hypothetical pathway for the activation of metabolic sialyltransferase inhibitors. Conditions:
a) cytosolic esterases, b) salvage pathway.

In a similar approach, Horstkorte et al. explored the activity of 5-N-acyl-modified sialic
acids on polysialyltransferases.192 The CHO-mutant 2A10 cells either ST8Sia II or ST8Sia IV
were fed with 5-N-acyl-D-mannosamines. The results showed that the artificial sialic acid
precursors bearing longer chains, i.e. propanoyl (53), butanoyl (54) and pentanoyl (55), at the
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5-position considerably reduced cell surface α-2,8-sialylation (Fig. 11). Real time RP-PCR
demonstrated that these compounds also affected gene expression. Unnatural sialic residues
were also found to be incorporated into sialoglycoconjugates. These results suggest the
formation of the corresponding CMP-Neu5Ac derivatives (56-58) which were prepared and
tested in a different study275 with consistent findings.

5. STRUCTURE-BASED DESIGN
A. Computational Tools and Docking
Computational tools constitute an attractive avenue for the design of new selective and potent
inhibitors. The recent characterisation of mammalian ST crystal structures have enabled
visualisation of the substrate-enzyme interactions highlighted by previous mutational studies.
As predicted, the donor binding site which is highly conserved between the different subtypes,
remains consistent while the major variations occur in the acceptor site (Fig. 12A and B).
Insight from crystal structures, such as rat and human ST6Gal I show many similarities.
Inhibitions in rat enzymes are thus likely to be translatable into human with acceptable error
aligning with biological results.
Using recent crystallographic data, research groups have started optimising new
inhibitors by structure-based design. Kumar et al. designed non-charged inhibitors and docked
them in the bacterial Cst-I enzyme (PDB: 2P2V).265 Chen et al. proposed a possible binding
mode for the steroidal inhibitor Lith-O-Asp (10) in pST3Gal I.55 Preidl et al. evaluated the
binding site of potent fluorescent probes by docking in the bacterial PmST1 (PDB: 2IHZ) and
pST3Gal I (2WNB).181 Montgomery et al. explored a range of donor and transition state
analogues towards the human ST6Gal I crystal structure. Molecular dynamics was performed
in order to validate the proposed mode of binding. Docking studies also reveal that
compounds considered as donor/transition state analogues, including 42, may in fact bind to
the acceptor site (Fig. 12C).276 Sujatha et al. established an homology model for the six
human ST3Gal I-VI by aligning their sequence with the bacterial enzyme Cst-II.277 Grewal et
al. later created homology models for the human ST6GalNAc I, ST3Gal III and ST8Sia I
using the crystal structure of the porcine ST3Gal I as a template and evaluated potential
binding sites for the natural products curcumin and resveratrol.278
Docking of the inhibitor 41 described by Hosogushi et al.180 into the pST3Gal I crystal
structure shows a possible binding mode that could explain its selectivity and potency. The
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steroidaal moiety apppears to fiit in the accceptor site while engaging H-bonnds with Th
hr215 and
Arg268 ((Fig. 12D).

Figure 12. (A) CMP-Neu5Ac 4 (green stickks) and accep
ptor sugar (orrange sticks)) in hST6Gall I (PDB
ID: 4JS
S2), and in (B
B) pST3Gal I (PDB ID: 22WNB), (C) the potent ph
henoxy derivvative 42 (R)) docked
in the active site of
o rST6Gal I (PDB ID: 4M
MPS) and (D
D) the steroid
dal CMP-Neuu5Ac derivattive 41
docked in
n the active siite of pST3G
Gal I (PDB ID
D: 2WNB)
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me of the most
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ytidine-base d inhibitorss will be thee focus heree (Table IV
V). Wang
et al. ellaborated a predictive 3D-QSAR
3
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model for α-2,6-ST
α
baased on com
mparative molecular
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field analysis. The authors pro
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a structure-ffunction anaalysis of hSST3Gal I.2255 Peptide
inhibitoors.279 Jeannneau et al. described
sequencce similaritiees have been examinedd by mutatio
onal analysiis and threee aminoacid residues
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(two histidine and a tyrosine residues) were found to be essential for the catalytic activity. By
using spin-labelled ligands, Liu et al. used an NMR study to identify the relative placement of the
donor and acceptor sites.226 These methods constituted good complements or even alternatives
to X-ray crystallography as most reported crystal structures were bacterial STs and the first
examples of mammalian STs were described only recently (cf Section 3).
Table IV. Structure-activity summary for cytidine-based ST inhibitors discussed in this review.
NH2
R1
Z
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Y

R2
X

N
N

linker

O

O

R3

2'

OH OH

Sugar mimic
Sugar mimic
ST3Gal
ST6Gal

ST8Sia

X
Y
Z
R1
R2
R3
R2

O >> NH > CH2
PO(OH)2 > CO2H > OH > H
O prefered on sugar-based derivative
PhO > HO(CH2)2O > glycerol > 4-NO2-C6H4-O
-NHAc > -OH > =O
OH prefered on sugar-based derivative
Elongated acyl chain

Nucleoside
Linker
Triazole
tolerated
Phosphate
optimal

Nucleoside
Substitution tolerated at 2’-position
Adenine not active
Cytidine preferred
5-FU analogues tolerated
Adenine, Resorcinol not active

Substitution tolerated at 2’- and 5-position

Comparing the inhibition data from the most active donor and transition-state analogue ST
inhibitors, the following SAR picture emerges for this class of inhibitor. The cytidine moiety
appears to play a key role in the interaction of ST inhibitors with the active site of ST6Gal I.
Any small change dramatically decreases the affinity. The linker between cytidine and the
sialic acid analogue is also of a great importance. A phosphate group, which acts as a leaving
group in the natural donor CMP-Neu5Ac, provides the optimal activity. Many other
functional groups have been evaluated, including amides, amino acids, sulfamides, triazole,
phosphoramide, phosphonate or even alkyl groups, however, all of these have afforded
inhibitors exhibiting lower potency. The presence of a negative charge or an acidic group in
the inhibitor appears to be favourable by interacting with the catalytic amino acid residues,
histidine or arginine, in the active site of the enzyme. This is particularly the case at position
Y, which replaces the carboxyl group of sialic acid.
The configuration of the carbon atom linking X and Y can be either sp2 or sp3, and in
several examples this position is a chiral centre. R or E configurations tend to be favoured at
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this centre, however, this is also dependent on the substituents attached. The left hand part of
the model represents the sialic acid mimic. The best results obtained to-date have been using
either a sugar derivative, e.g. pyrane ring, or by replacing the complex highly functionalised
sialic acid ring by an aromatic ring. The presence of a heteroatom at Z, to mimic the pyranyl
oxygen atom of the natural donor, is also favourable. An oxygen atom at this position results
in greater affinity than a nitrogen atom, which is greater than a carbon atom, suggesting a
possible H-bond interaction with a polar residue in the active site.
R1 refers to the polyhydroxylated side chain of sialic acid. A phenoxy group at R1 has so
far provided the greatest affinity, offering easier and cheaper synthetic pathways than a sugar
related chiral polyol. The various ST crystal structures often reveal the presence of several
hydrophobic residues in this location of the active site, suggesting that aromatic stacking
interactions may occur between the phenyl group and a tryptophan or tyrosine residue. The
selectivity achieved between the different enzyme subtypes in recent reports indicates that
positions R2 and R3 could be interesting tools in the future for developing new selective
inhibitors.

6.
COMPOUNDS
WITH
SIALYLTRANSFERASES

INDIRECT

ACTIVITY

ON

In the T84 colon cancer cell line, the secondary bile acid, deoxycholate (DOC, 59) and the
phorbol ester, 12-O-tetradecanoylphorbol-13-acetate (TPA, 60) were found to decrease
expression of ST6Gal I to 30% and 13% of the control respectively, mediated by Ca2+ and
protein kinase C (Fig. 13).280 Similar results were previously observed while examining the
influence of sodium butyrate on MUC1 expressing Panc1 pancreatic cancer cell line.281 Gene
expression was monitored by real time PCR for ST3Gal III, ST3Gal IV, ST3Gal VI as well as
some glycosyltransferases and β-actin.
Triptolide (61) is an immunosuppressive and antiinflammatory diterpenoid epoxide
isolated from the perrenial vine Tripterygium wilfordii (thunder god vine) native to China,
Japan and Korea (Fig. 13).282,283 The vine has been used in Traditional Chinese Medicine for
centuries for treating inflammation, in particular rheumatoid arthrisits, and autoimmune
diseases. Triptolide, one of the major active constituents of the vine, has been shown to inhibit
cell proliferation in leukemia, neuroblastoma, pancreatic, ovarian, gastric and lung cancer cell
lines.284,285 Various modes of action have been ascribed to triptolide including its ability to
cause apoptosis via inhibition of HSP70286,287 and by blocking TNF-alpha-induced activation of
NF-kappa B.288 Interestingly, triptolide has also been found to downregulate human GD3
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synthase (hST8Sia I) gene expression in SK-MEL-2 human melanoma cells.289,290 Triptolide
has reduced growth and metastasis of tumours in various rodent models including polycystic
kidney disease,291 neuroblastoma, melanoma, and pancreatic, breast and gastric cancers,
including S2-013, one of the most aggressive pancreatic-tumour derived cell lines.292,293 The
antitumour effect of triptolide was found to be comparable or superior to a range of
conventional antitumour drugs including Taxol, doxorubicin, and cisplatin, as well as
retaining activity towards drug-resistance cell lines in cell culture studies.293 In addition to its
antitumour activity, triptolide 61 has multiple reported functions, including immunosuppresive,
antiinflammatory, and antifertility activity, and is also emerging as a promising new candidate
for Alzheimer’s disease based on its ability to inhibit BACE1 in a transgenic mouse model.294
Accordingly, there are several synthetic studies on triptolide and its analogues sinces its first
report.295-299 Although its physical properties have limited triptolide’s therapeutic potential, a
synthetic prodrug analogue, minnelide (62), is showing equal promise including against
tumour-initiating cells responsible for treatment relapse in pancreatic cancer, with minnelide
currently in Phase I clinical trials for pancreatic and advanced gastrointestinal cancers at the
time of writing (Fig. 13).300-305

Figure 13. Natural product derived and synthetic analogues with indirect inhibitory activity on STs.

Although there is only one study reporting the ST inhibitory activity of triptolide in
melanoma, the diverse range of functions of this compound and potent activity towards high
ST-expressing cancers such as pancreatic and ovarian cancer (see Fig. 4), including their drug-
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resistant cell lines, raise the possibilty that disruption of cell surface sialylation may play a key
role in this compound’s activity in a wide range of diseases.
Sialyl Lewisx is an important tumour-associated carbohydrate antigen present on cell
surface glycoconjugates involved in leukocyte migration and cancer metastasis.
Radhakrishnan et al. reported the formation of sLex epitope in butyrate-treated human
pancreatic

adenocarcinoma

cells

expressing

MUC1

and

core

2

N-

acetylglucosaminyltransferase (C2GnT).281 Butyrate treatment stimulates not only the
transgene but also a group of endogenous GT genes involved in the synthesis of sLex. 5-Aza2-deoxycytidine increases sLex production on MUC1 through induction of ST3Gal VI gene
by inhibiting its methylation in colon cancer cell lines.306 Similar results were observed in
ovarian cancer, which led to question the validity of using 5-Aza-dC (63) as a treatment as
potentially facilitates cancer progression and metastasis.307 In a different fashion, cytarabine
(64) promotes decreased cell surface sialylation in normal human lung tissue (WI-38 cells)308
and acute leukemia (HL-60 cells)309 by inhibiting CMP-Neu5Ac synthetase via the active
metabolite araCMP (Fig. 13).
Calnexin and Calreticulin are transmembrane chaperones in the endoplasmic reticulum
involved in folding a number of glycoproteins and regulate their uptake in the Golgi
apparatus. Calnexin was found to bind to ST8Sia I, the GD3 synthase.310 As GD3 is produced
by responding to environmental stressors, the inactivation of ST8Sia I contributes to regulate
many biological processes such as apoptosis. Significant increase in Calnexin and calreticulin
levels were observed in mice with ST3Gal II transgenes.311

7. BIOLOGICAL TOOLS TOWARDS IMAGING
Labelling and tracking have become techniques of increasing importance in modern
biotechnology which are progressively reinforced by advances in material science.312 This
method enables visualization in cells and organisms as well as the enrichment of specific
glycoprotein types for proteomic analysis. In addition to the therapeutic potential of ST
inhibitors, labelled sialic acid and sialic acid analogues are also being explored for their
diagnostic and prognostic value in imaging sialylation in disease. There are a host of methods
for interrogating cell-surface sialylation based either on the affinity of natural sialosides for
specific lectins, biosynthetic incorporation of unnatural sialic acids into cell surface
glycoproteins that are subsequently detected with complementary labelled substrates, or direct
incorporation of a labelled entity such as FITC-Neu5Ac.313
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A. Metabolic Glycoengineering
Exploitation of the promiscuous glycosylation biosynthetic machinery has allowed the
incorporation of a wide range of unnatural sialic acids and their biogenetic precursors (e.g.,
ManNAc, Neu5Ac, and CMP-Neu5Ac analogues) into living cells and animals.314,315 Once
expressed on the cell surface (which can take from just minutes to hours) the functionalised
sialic acid (typically bearing a free ketone-, azide-, thiol-, or alkyne-moiety) is subjected to a
bioorthogonal chemoselective ligation reaction to a labelled counterpart.316 Metabolic
glycoengineering is a rapidly expanding field that was pioneered by C. Bertozzi from
Stanford and has been reviewed in detail elsewhere.315 Herein selected recent examples are
included to illustrate the power of this technique in uncovering more about the integral role of
sialylation in both disease and normal biological process.
The azide groups being virtually absent in nature constitutes an excellent building block
for selectively tagging a biomolecular entity. The ‘clickable’ reagent can be introduced using
a cell-permeable biogenetic precursor of CMP-Neu5Ac bearing an azido or alkynyl group.317
Once this building block has entered the cell, it utilises the biosynthetic machinery to provide
the corresponding sialic acid derivative, allowing the reactive residue to appear as a cell
surface modified glycan.314,315 This concept efficiently allows the incorporation of a modified
moiety on the cell surface. In this manner, a wide range of modified ManNAc analogues have
been biosynthetically incorporated into cell surface glycoproteins, with peracetylation
significantly enhancing cellular uptake of ManNAc analogues (although it has less of an
effect on sialic acid analogues).318 In particular, peracetylated N-azidoacetylmannosamine,
Ac4ManNAz (65, Fig. 14), has proven a versatile substrate for copper-free click chemistry319
or a Staudinger ligation320 for dynamic in vivo imaging in various animal models including
drosophila larvae,321 mice,322,323 rat,324 and zebrafish.196,325 For example, Ac4ManNAz has
been employed for the site-specific labelling of the heavy chain, N-glycosylation site of an
anti-CA 19-9 antibody and used for in vitro and in vivo targeting of pancreatic cancer cells.326
Ac4ManNAz has also been used to visualise the dynamic sialylation processes occurring
during epithelial-mesenchymal transition (EMT) in human keratinocyte HaCaT cells via click
labelling with fluorophores and affinity tags. In addition, incorporating the commercially
available pan-sialylation inhibitor P-3Fax-Neu5Ac (50), it was found that inhibition of global
sialylation promoted EMT.327
Many modified ManNAc and Neu5Ac analogues are commercially available promoting
further development of this field. In addition, the corresponding alkynyl sugar derivatives
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such as Neu5Hex (66) have been applied in an analogous manner to couple with azidobearing labels (Fig. 14).328 For example, Homann et al. metabolically incorporated Neu5Hex
into the cell-surface glycocalyx of a human larynx carcinoma cell line (HEp-2), which was
then labelled with a fluorescence tag using click chemistry.329 Jiang et al. utilised
peracetylated N-(4-pentynoyl) mannosamine (Ac4ManNAl), an alkyne-tagged metabolic
precursor of sialic acid, to monitor the kinetics of glycan biosynthesis. Coupling this with an
electron-donating picolyl azide and BTTPS, a tris(triazolylmethyl)amine-based Cu(I)chelating ligand, accelerated efficiency of the CuAAC reaction 20-38-fold. In mammalian
cells they reported that it takes 30-45 min for incorporation of ManNAc analogues into cellsurface glycoconjugates, and were able to detect labelled glycans in zebrafish embryos at the
two-cell stage (0.75–2 hpf).330
Photo-cross linking diazirine-modified N-acetylmannosamine (ManNAc) have also been
incorporated into cell surface glycoconjugates in BJA-B, Daudi, and Jurkat cells.331 Upon
exposure to UV irradiation, they were covalently cross-linked to sialic acid binding partners
such as Siglec CD22. The compounds were nontoxic and exhibited minimal growth inhibition
at the testing concentrations. Expanding on this, dual metabolic labelling of sialylated glycans
using bifunctional sialic acid analogues containing two distinct chemical reporters at the Nacyl side chain and C9 positions, such as an azide for click labelling and a diazirine for photo
cross linking, have been described.332 The bifunctional sialic acid analogues 9AzSiaNAl and
9AzSiaDAz (67) were metabolically incorporated into cellular glycans in Daudi B
lymphoblast cells and used for two-colour and FRET imaging (Fig. 14).
B. Fluorescence Imaging
Preidl et al.181 developed a series of fluorescent mimetics, e.g. 43 of CMP-Neu5Ac based on
classical Schmidt type ST transition-state analogue inhibitors 42.266 The polyanionic
fluorescent compounds were efficiently taken up into cells and translocated to compartments
surrounding the cell nucleus without the need for transfection agents (Fig. 14). All probes
examined were found to bind to the four commercially available STs employed in their study,
rST3Gal II, hST6Gal I, and bacterial STs 24PmST1 from Pasteurella multocida and
Pd2,6ST(N) from Photobacterium damsela. All exhibited nanomolar ST inhibitory activity in
a fluorescence polarisation based displacement assay with Ki values in the range of 0.66-0.88
M against the mammalian STs and 0.08-0.39 M against bacterial STs.181
Wu et al.313 have recently illustrated the clinical potential for fluorescence guided
intraoperative tumour detection using FITC-labelled sialic acid (FITC-Neu5Ac) (68), which is
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taken up by a broad range of tumour cell lines in vitro including Raw 264.7 macrophages,
human epithelial carcinoma (HeLa), human hepatocellular carcinoma (QGY-7701), human
primary glioblastoma (U87-MG), H22 hepatocellular carcinoma, murine microglial cells (BV2) and the human embryonic kidney 293 cells (normal tissue). The FITC-Neu5Ac is
metabolically incorporated into glycoproteins via a cellular sialylation pathway and
transported to the cell surface where it is imaged. Furthermore, intravenous injection of FITCSA into ICR mice with subcutaneous tumours revealed preferential uptake by tumours in vivo,
including high target-to-background fluorescence ratios. Live cell imaging using a CMPNeu5Ac analogue carrying a fluorescent reporter group was also described by Suzuki et al.
The compound was found to be a substrate of a CMP-sialic acid transporter and enabled
visualisation of specific Golgi vesicles.333
Non-invasive imaging of intracellular ST activity has been described using
tetramethylrhodamine isothiocyanate labeled asialofetuin (TRITC-AF) as a ST substrate and
fluorescein isothiocyanate-labeled 3-aminophenylboronic acid (FITC-APBA), which forms a
stable chemoselective complex with Neu5Ac at physiological pH. The FITC and TRITC
donor and acceptor FRET pair is encapsulated in a liposome vesicle for intracellular delivery.
This method can be used to determine ST activity and cell surface sialylation and evaluate
correlations with malignancy, as well as assessing activity of ST inhibitors.334

Figure 14. Examples of sialic acid derivatives or mimics used for imaging.
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C. Biomarkers and Biosensors
The over-expression of sialylated epitopes such as sialyl Lewisa (sLea); sialyl Lewisx (sLex);
sialyl Tn (sTn); disialylated gangliosides GD2 and GD3; monosialylated gangliosides GM1
and GM2; and polysialic acid (PSA), on the cancer cell surface has been well known for
decades and forms the basis of many existing serum tumour markers on the market including
carbohydrate antigen CA 19-9 (sLea) for pancreatic cancer.9 The identification of new highly
sensitive biomarkers for early detection and monitoring of disease is a rapidly expanding area
and one where a greater understanding of tumour glycosylation and sialylation has immense
potential to contribute to the development of new diagnostic methods.48,335,336 In addition to
these ‘natural’ tumour-associated carbohydrate antigens (TACAs), the xeno-autoantigen
Neu5Gc (2), acquired predominantly from red meat diets and detected in high levels in human
cancers, also provides a potential target for immunotherapy.335,337,338 There are also increasing
reports on the development of ultrasensitive biosensors for detecting specific sialylated
glycans for cancer diagnosis. These include gold nanoparticle bound Sambucus nigra
agglutinin (SNA) based sensors that bind specifically to α-2,6-sialylated glycans with
detection limits of 0.03 pg.mL−1; Prussian blue-based nanocomposite sensors; and boronic
acid-functionalized peptide-based fluorescent sensors with a high specificity for sLex cellsurface glycans.339-341
In a different glycoproteomic approach, CMP[14C]Neu5Ac and ST3Gal II were used in
an 'exchange sialylation' process to radiolabel and characterise cancer-associated mucin type
O-glycans, which resulted in the identification of a unique 25-35 kDa sialylated glycoprotein
in pancreatic tumours.342

8. CONCLUSIONS
Our ever-expanding knowledge of the intricate role of sialylation in cancer,
inflammation, immunology and central nervous system disorders, has highlighted the
therapeutic potential of this important family of enzymes. Today, an overwhelming number of
studies have established the merits of inhibiting specific STs such as ST3Gal I and ST6Gal I,
as a powerful new anti-metastatic strategy, with the potential to be effective on drug-resistant
tumours. A small number of pan-ST inhibitors are commercially available, however, for ST
inhibitors to proceed to the clinical stage, it is essential that selective inhibitors for the
different ST subtypes are developed to specifically target those STs over-expressed in cancers
and to reduce off-target effects. A wide variety of inhibitors have been developed over the last
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two decades both by rational design and from natural product and high-throughput screening
efforts. The recent reports of mammalian crystal structures for porcine ST3Gal I, rat and
human ST6Gal I and human ST8Sia III, has enabled the use of structure-based design to drive
ST inhibitors design in the future to improve inhibitor selectivity and pharmacokinetic
profiles. Increased availability of subtype selective, cell-permeable and synthetically
accessible, small-molecule ST inhibitors in the future will enable further exploration and
therapeutic exploitation of the role of sialylation in a range of diseases, in particular metastatic
cancers. In addition to their potential therapeutic role, sialyltransferase inhibitors and their
analogues are also being explored as diagnostic tools for disease imaging.
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ABBREVIATIONS
CDP = Cytidine diphosphate
CHO = Chinese Hamster Ovary cells
CMP = Cytidine monophosphate
CMP-3F-Neu5Ac = Cytidine-5′-monophospho-N-acetyl-3-fluoroneuraminic acid
CMP-Neu5Ac = Cytidine-5′-monophospho-N-acetylneuraminic acid
COX-2 = cyclooxygenase-2
CTP = Cytidine triphosphate
EMT = epithelial–mesenchymal transition
FAK = Focal adhesion kinase-1
FITC = Fluorescein isothiocyanate
FP = fluorescence polarization
FUT3 = Fuc-α-1,3/4-Gal-β-1,4/3-GlcNAc-specific galactoside 3(4)-L-fucosyltransferase
FUT6 = Fuc-α-1,3-Gal-β-1,4-GlcNAc-specific α-(1,3)-fucosyltransferase
FUT7 = Fuc-α-1,3-Gal-β-1,4-GlcNAc-specific α-(1,3)-fucosyltransferase
G6P = glucose-6-phosphate
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GT = Glycosyltransferase
GWAS = Genome wide association study
hST = Human sialyltransferase
HTS = high-throughput screening
Lith = Lithocholic acid
LOS = lipooligosaccharide
MDR = Multi-Drug Resistance
MM = multiple myeloma
MS = mass spectrometry
MUC1 = mucin 1
NCAM = Neutral cell adhesion molecule
Neu5Ac = N-Acetylneuraminic acid (sialic acid)
Neu5Gc = N-Glycolylneuraminic acid
PDB = Protein data bank
pST = Porcine sialyltransferase
rST = Rat sialyltransferase
SAR = Structure-Activity Relationship
ST = Sialyltransferase
Sia6LacNAc = Sia-α-2,6-Gal-β-1,4-GlcNAc
sLea = sialyl Lewisa
SLex = sialyl Lewisx
SSEA4 = stage-specific embryonic antigen 4
ST = sialyltransferase
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